Research programme: monoclonal antibodies - Viral Hemorrhagic Fever Consortium/Zalgen Labs

Drug Profile

Research programme: monoclonal antibodies - Viral Hemorrhagic Fever Consortium/Zalgen Labs

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viral Hemorrhagic Fever Consortium; Zalgen Labs
  • Developer Tulane University; University of Rochester; University of Texas Medical Branch; Zalgen Labs
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lassa fever
  • Research Ebola virus infections; Lymphocytic choriomeningitis virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 16 Jun 2017 Early research in Lymphocytic choriomeningitis virus infections in USA (Parenteral) before June 2017 (Zalgen labs pipeline, June 2017)
  • 16 Jun 2017 Early research in Ebola virus infections in USA (Parenteral) before June 2017 (Zalgen labs pipeline, June 2017)
  • 26 Sep 2016 Zalgen Labs along-with Tulane University and University of Texas agree to co-develop monoclonal antibodies for Infections before September 2016 (Zalgen Labs pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top